Biogen

Company Overview

Biogen is a global biopharmaceutical company focused on developing and delivering drugs for complex, hard-to-treat diseases, including rare and neurodegenerative diseases. It is focused on conditions like multiple sclerosis (MS), Alzheimer’s disease and spinal muscular atrophy (SMA). Biogen is recognized for its MS treatments and continues to develop innovative therapies in neuroscience. In addition to branded drugs, it also manufactures and markets biosimilars.

Biogen's primary monoclonal antibody (mAb) is Tysabri (natalizumab), used to treat multiple sclerosis and Crohn’s disease. Its biosimilar portfolio includes Flixabi (infliximab) and Imraldi (adalimumab). Its other products include Avonex, Plegridy, Tecfidera, Vumerity, Fampyra, Fumaderm, and Benepali.

Financial Highlights (FY 2025)

Company's Business Segments

• Multiple Sclerosis : The segment develops, manufactures, and markets various products designed to treat patients with M.S.
• Rare Disease : This segment includes SPINRAZA for SMA and SKYCLARYS for F.A., which was obtained as part of its acquisition of Reata in.
• Biosimilars : September 2023 and QALSODY for ALS, which became commercially available in the U.S. during Q2, 2023.
• Others Revenue : Revenue from anti-CD20 therapeutic programs, Alzheimer's collaboration revenue, Contract manufacturing, royalty and other revenue